drugset

drugset / Trial / NCT06616727

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM

NCT06616727 ↗

Phase 1 Enrolling by invitation 50 enrolled Shanghai Simnova Biotechnology Co.,Ltd.

NaSingle-groupOpen-labelTreatment

Summary

A phase I study to evaluate the safety, tolerance and pharmacokinetics of SNC109 in patients with rGBM

Timeline

Start: 2023-12-26
Primary completion: 2024-12-31
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SNC109	Cell therapy	50000 cells	—

Indications